Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Recurrent Laryngeal Nerve Monitoring During Pediatric Aerodigestive Tract and Cardiac Surgery

19 de mayo de 2026 actualizado por: Andre Isaac, University of Alberta

Recurrent Laryngeal Nerve Monitoring During Pediatric Aerodigestive Tract and Cardiac Surgery: A Randomized Double-blinded Controlled Trial

This research studies whether a device used during surgery can help doctors better protect the nerve that moves a child's vocal cords. Damage to this nerve can affect speaking, swallowing, and sometimes breathing. Children having certain throat, chest, or heart surgeries may be asked to take part. During surgery, some children will have standard care and others will have standard care plus the nerve-monitoring device. After surgery, the team will check vocal cord movement and ask about voice and swallowing. The purpose is to see whether the device can lower the chance of nerve injury and improve care for children in the future.

Descripción general del estudio

Descripción detallada

Purpose The purpose of this study is to compare the rate of recurrent laryngeal nerve (RLN) injury in pediatric patients undergoing aerodigestive and cardiac surgeries with intraoperative laryngeal nerve monitoring (IOLNM) versus standard surgery without IOLNM. The study also aims to evaluate whether continuous electromyography monitoring reduces clinically detectable postoperative nerve dysfunction in children undergoing RLN-risk surgery.

Hypothesis The investigators hypothesize that patients who undergo surgery with IOLNM will have a lower rate of RLN injury, less severe nerve injury when injury occurs, and a shorter duration of neuropraxia/vocal cord paresis compared with patients who undergo standard surgery without monitoring.

Justification Vocal cord paralysis is a recognized complication of pediatric thyroid, airway, esophageal, and cardiac surgery because the RLN is vulnerable along its course through the neck and chest. RLN injury can lead to dysphonia, dysphagia, aspiration, and respiratory insufficiency, making prevention clinically important. Existing evidence suggests IOLNM may reduce RLN injury, especially in pediatric surgery where some procedures have reported injury rates as high as 40%; however, the current literature is limited by a lack of prospective randomized studies and lack of direct prospective comparison against standard surgical care. The recent availability of pediatric-compatible monitoring electrodes also makes this question feasible to study in infants and young children.

Research Method/Procedures This is a single-centre, randomized, double-blinded, controlled clinical trial conducted at Stollery Children's Hospital. Eligible participants are patients under 18 years of age undergoing RLN-risk surgery involving the trachea, esophagus, thyroid, mediastinum, ductus arteriosus, or aortic arch, with specified inclusion and exclusion criteria. Participants, study investigators, clinicians performing follow-up flexible laryngoscopy, and video raters are blinded to allocation; surgeons and personnel directly involved in intraoperative care cannot be blinded.

For participants randomized to the intervention arm, IOLNM is used during a single surgery. Surgery otherwise proceeds according to standard of care. Within four weeks of their surgery, participants are seen in follow-up by Dr. Isaac or another pediatric otolaryngologist. At that visit, they complete the PedsQL, PVRQOL, Pediatric VHI, and dysphagia questionnaires, and undergo video-recorded flexible fiberoptic laryngoscopy. The recorded laryngoscopy is anonymized and reviewed by a blinded independent expert. For patients with RLN injury, further clinical follow-up and repeat laryngoscopy every three months for at least one year or until recovery occur as part of standard care.

Safety monitoring is performed during surgery, the postoperative hospital stay, and follow-up visits. Adverse events related to IOLNM include, but are not limited to, laryngeal trauma, airway bleeding, or inflammation, and are reported to the study coordinator, principal investigator, and local HREB in accordance with institutional and Health Canada standards.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

90

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Andre Isaac
  • Número de teléfono: 17804071449
  • Correo electrónico: aisaac@ualberta.ca

Ubicaciones de estudio

    • Alberta
      • Edmonton, Alberta, Canadá, T6G2B7
        • Stollery Children's Hospital
        • Contacto:
          • Andre Isaac, MD, MSc, FRCSC
          • Número de teléfono: 7804071449
          • Correo electrónico: aisaac@ualberta.ca
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño
  • Adulto

Acepta Voluntarios Saludables

Sí

Descripción

Inclusion Criteria:

  • under 18 years of age
  • treated at the Stollery Children's Hospital
  • will undergo specified aerodigestive or cardiac surgeries that put the recurrent laryngeal nerve at risk

Exclusion Criteria:

  • patients treated at another center
  • over 18 years of age at the time of surgery
  • severe neurological or genetic comorbidities that affect nerve function

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Sin intervención: Control Arm
Participants in this arm will receive standard care during surgery, without the use of intra-operative laryngeal nerve monitoring.
Experimental: Intervention Arm
Participants enrolled in this arm will receive intra-operative recurrent laryngeal nerve monitoring during their surgery to determine if this intervention reduces the risk of developing recurrent laryngeal nerve injury.
This nerve monitor will notify surgeons if the recurrent laryngeal nerve is at risk for damage during surgery, by signalling if the nerve is being stretched or manipulated throughout the procedure.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Vocal fold mobility
Periodo de tiempo: Flexibly laryngoscopy will be performed within four weeks of the aerodigestive or cardiac surgery.
Vocal fold mobility will be assessed by flexible laryngoscopy on patients post operatively to determine if there has been RLN injury resulting in vocal cord immobility.
Flexibly laryngoscopy will be performed within four weeks of the aerodigestive or cardiac surgery.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Impact on voice in UVFI patients
Periodo de tiempo: The questionnaire will be given within four weeks of the UVFI diagnosis.
Voice-related quality of life questionnaire
The questionnaire will be given within four weeks of the UVFI diagnosis.
Severity of dysphonia in UVFI patients
Periodo de tiempo: Voice assessment will be completed within four weeks of UVFI diagnosis
Dysphonia measured by acoustic analysis and GRBAS assessment
Voice assessment will be completed within four weeks of UVFI diagnosis
Swallowing outcomes in UVFI patients
Periodo de tiempo: Swallowing assessments will be completed within four weeks of UVFI diagnosis and as recommended by SLP/ENT
Dysphagia will be measured by FEES and/or VFSS assessments
Swallowing assessments will be completed within four weeks of UVFI diagnosis and as recommended by SLP/ENT
Swallowing symptom burden in UVFI patients
Periodo de tiempo: Questionnaires will be given within four weeks of UVFI diagnosis
Impact on quality of life from dysphagia will be measured using validated questionnaires
Questionnaires will be given within four weeks of UVFI diagnosis
Rate of spontaneous resolution of UVFI
Periodo de tiempo: These outcomes will be measured by flexible laryngoscopy at 3 month and 6 month intervals after the time of UVFI diagnosis
Rate of vocal fold motion recovery, and time to recovery, assessed by flexibly laryngoscopy
These outcomes will be measured by flexible laryngoscopy at 3 month and 6 month intervals after the time of UVFI diagnosis

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de septiembre de 2026

Finalización primaria (Estimado)

30 de junio de 2028

Finalización del estudio (Estimado)

30 de junio de 2028

Fechas de registro del estudio

Enviado por primera vez

12 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

19 de mayo de 2026

Publicado por primera vez (Actual)

22 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

22 de mayo de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

19 de mayo de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir